Literature DB >> 8498369

Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension.

R Pacher1, J Bergler-Klein, S Globits, H Teufelsbauer, M Schuller, A Krauter, E Ogris, S Rödler, M Wutte, E Hartter.   

Abstract

Plasma endothelin concentrations were evaluated in 53 chronic, congestive heart failure (CHF) patients with or without history of systemic hypertension, as well as in 9 with hypertension only and in 22 healthy control subjects. Plasma renin, aldosterone and atrial natriuretic peptide, as well as clinical and hemodynamic data were determined. In patients with CHF, big endothelin-1 was, independent of hypertension history, significantly greater than in hypertensive patients with normal cardiac function and in control subjects (both p < 0.0001). Patients with severe CHF had significantly greater big endothelin-1 values than did those with moderate CHF. During 12-month follow-up, 11 patients with CHF underwent heart transplantation, and 9 died; these patients had significantly greater big endothelin-1 concentrations than did the 33 clinically stable patients (p < 0.001). Big endothelin-1 and atrial natriuretic peptide correlated with right atrial pressure, pulmonary capillary wedge pressure, left ventricular ejection fraction, effort capacity and severity of CHF (New York Heart Association functional class).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8498369     DOI: 10.1016/0002-9149(93)90543-l

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

Review 1.  Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure.

Authors:  H Krum; R Denver; A Tzanidis; P Martin
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

2.  Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.

Authors:  N C Davidson; W J Coutie; D J Webb; A D Struthers
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

Review 3.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 4.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 5.  Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists?

Authors:  Gian Paolo Rossi
Journal:  Curr Hypertens Rep       Date:  2006-06       Impact factor: 5.369

Review 6.  Endothelin in congestive heart failure.

Authors:  M P Love; J J McMurray
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

Review 7.  Endothelin antagonists and heart failure.

Authors:  David Hürlimann; Frank Enseleit; Georg Noll; Thomas F Lüscher; Frank Ruschitzka
Journal:  Curr Hypertens Rep       Date:  2002-02       Impact factor: 5.369

8.  Localization and function of ET-1 and ET receptors in small arteries post-myocardial infarction: upregulation of smooth muscle ET(B) receptors that modulate contraction.

Authors:  G A Gray; E J Mickley; D J Webb; P E McEwan
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

Review 9.  Endothelin and heart failure.

Authors:  P Nambi; M Clozel; G Feuerstein
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

10.  Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group.

Authors:  A M Richards; M G Nicholls; T G Yandle; H Ikram; E A Espiner; J G Turner; R C Buttimore; J G Lainchbury; J M Elliott; C Frampton; I G Crozier; D W Smyth
Journal:  Heart       Date:  1999-02       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.